CTx-1301 - Dexmethylphenidate 25mg + CTx-1301 - Dexmethylphenidate 37.5mg + CTx-1301 - Dexmethylphenidate 50mg + Placebo

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

ADHD

Conditions

ADHD, ADHD - Combined Type, Attention Deficit Hyperactivity Disorder Combined, Attention Deficit Hyperactivity Disorder

Trial Timeline

Dec 29, 2022 → Jun 13, 2023

NCT ID

NCT05631626

About CTx-1301 - Dexmethylphenidate 25mg + CTx-1301 - Dexmethylphenidate 37.5mg + CTx-1301 - Dexmethylphenidate 50mg + Placebo

CTx-1301 - Dexmethylphenidate 25mg + CTx-1301 - Dexmethylphenidate 37.5mg + CTx-1301 - Dexmethylphenidate 50mg + Placebo is a phase 3 stage product being developed by Cingulate for ADHD. The current trial status is completed. This product is registered under clinical trial identifier NCT05631626. Target conditions include ADHD, ADHD - Combined Type, Attention Deficit Hyperactivity Disorder Combined.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05631626	Phase 3	Completed	Dec 29, 2022	Jun 13, 2023	ADHD

Competing Products

20 competing products in ADHD

See all competitors

Product	Company	Stage	Hype Score
atomoxetine	Eli Lilly	Approved	85
Strattera (atomoxetine)	Eli Lilly	Approved	85
Atomoxetine + placebo	Eli Lilly	Approved	85
Atomoxetine Hydrochloride + placebo	Eli Lilly	Approved	85
atomoxetine (Strattera)	Eli Lilly	Approved	85
Atomoxetine + stimulants (any approved ADHD medication)	Eli Lilly	Pre-clinical	23
dasotraline + Placebo	Sumitomo Pharma	Phase 3	77
dasotraline	Sumitomo Pharma	Phase 1	33
dasotraline 4mg	Sumitomo Pharma	Phase 3	77
AZD1446 + AZD1446 + AZD1446 + Placebo	AstraZeneca	Phase 2	52
Placebo + AZD3480 + AZD3480	AstraZeneca	Phase 2	52
MK0249 + Concerta (methylphenidate) + Placebo	Merck	Phase 2	52
Focalin XR	Novartis	Phase 3	77
Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR) + Placebo	Novartis	Approved	85
Dexmethylphenidate HCl extended-release capsules	Novartis	Phase 3	77
Methylphenidate hydrochloride	Novartis	Phase 3	77
Focalin XR	Novartis	Phase 3	77
methylphenidate HCl ERCT + Placebo	Pfizer	Approved	84
methylphenidate HCl ERCT	Pfizer	Approved	84
Very Low Dose Quillivant XR + Low Dose Quillivant XR + Moderate Dose Quillivant XR	Pfizer	Approved	84

Other Products from Cingulate

CTx-1301-Dexmethylphenidate 12.5 mg (titration only) + CTx-1301-Dexmethylphenidate 18.75mg (randomized fixed dose) + CTx-1301-Dexmethylphenidate 25mg (randomized fixed dose) + CTx-1301-Dexmethylphenidate 37.5 mg (randomized fixed dose) + PlaceboPhase 3

CTx-1301 - Dexmethylphenidate 6.25mg + CTx-1301 - Dexmethylphenidate 12.5mg + CTx-1301 - Dexmethylphenidate 18.75mg + CTx-1301 - Dexmethylphenidate 25.0mg + CTx-1301 - Dexmethylphenidate 31.25mg + CTx-1301 - Dexmethylphenidate 37.5mg + PlaceboPhase 3

Dexmethylphenidate 5 Mg Oral Capsule, Extended Release + Dexmethylphenidate 6.25 mg Tablet + Dexmethylphenidate 40 Mg Oral Capsule, Extended Release + Dexmethylphenidate 50 mg TabletPhase 1/2

DexmethylphenidatePhase 1